New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
May 15, 2014
12:25 EDTBMY, BMY, BMY, EXEL, EXEL, EXEL, JNJ, JNJ, JNJ, MDVN, MDVN, MDVN, MRK, MRK, MRK, OGXI, OGXI, OGXI, RHHBY, RHHBY, RHHBYLeerink pharma and biotech analysts hold an analyst/industry conference call
Biotech and Pharmaceuticals Analysts provide updates on GU cancer, in conjunction with the upcoming ASCO Annual Meeting where relevant companies BMY, EXEL, JNJ, MDVN, MRK, OGXI and RHHBY may be discussed on the Analyst/Industry conference call to be held on May 22 at 1 pm.
News For BMY;EXEL;JNJ;MDVN;MRK;OGXI;RHHBY From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | 3 | 4 | all recent news | >>
April 10, 2015
14:39 EDTJNJJohnson & Johnson April volatility elevated into Q1 and outlook
Johnson & Johnson April call option implied volatility is at 20, May is at 16, June is at 15, October is at 14; compared to its 26-week average of 16 according to Track Data, suggesting large near term price movement into the expected release of Q1 results on April 14.
April 9, 2015
09:25 EDTJNJ, MRKPiper Jaffray pharmaceuticals analysts hold an analyst/industry conference call
Subscribe for More Information
08:32 EDTEXELExelixis' cabozantinib granted FDA fast track designation
Exelixis announced that the U.S. Food & Drug Administration has granted Fast Track designation to cabozantinib for treatment of patients with advanced renal cell carcinoma who have received one prior therapy. Cabozantinib is the company’s lead compound and inhibits the activity of multiple tyrosine kinases including MET, VEGFRs and RET. The FDA created the Fast Track process to facilitate the development and expedite the review of drugs to treat serious diseases and address unmet medical needs. Fast Track designation confers important benefits, including the potential eligibility for Priority Review of a New Drug Application, if relevant criteria are met.1 Cabozantinib is the subject of METEOR, an ongoing phase 3 pivotal trial in patients with metastatic RCC who have experienced disease progression following treatment with at least one VEGFR tyrosine kinase inhibitor. Patients are randomized 1:1 to receive 60 mg of cabozantinib daily or 10 mg of everolimus daily. The primary endpoint of METEOR is progression-free survival, and secondary endpoints include overall survival and objective response rate. Exelixis expects to release top-line results from the trial in the second quarter of 2015. In addition to the metastatic RCC development program, Exelixis is also evaluating cabozantinib in CELESTIAL, a phase 3 pivotal trial in second-line hepatocellular carcinoma.
April 8, 2015
15:19 EDTRHHBYRoche says receives European approval for Avastin plus chemotherapy
Roche announced that the European Commission approved Avastin -- bevacizumab -- in combination with standard chemotherapy for the treatment of adult patients with persistent, recurrent or metastatic carcinoma of the cervix. The EU approval was based on the significant survival benefit in the pivotal GOG-0240 study, which showed that women who received Avastin plus chemotherapy had a statistically significant 26% reduction in the risk of death, representing a median improvement in survival of nearly four months, compared to women who received chemotherapy alone.
09:23 EDTJNJJohnson & Johnson April volatility elevated into Q1 and outlook
Subscribe for More Information
08:08 EDTBMYuniQure price target raised to $50 from $28 at Leerink
Subscribe for More Information
08:06 EDTBMYBristol-Myers completes acquisition of Flexus Biosciences
Bristol-Myers Squibb Company announced that it has completed the previously announced planned acquisition of Flexus Biosciences, Inc. The transaction includes full rights to F001287, Flexus’ lead preclinical, small-molecule IDO1-inhibitor targeted for IND filing in the second half of 2015 and an IDO/TDO discovery program that includes its IDO-selective, IDO/TDO dual and TDO-selective compound libraries. A newly formed entity established by the current shareholders of Flexus will retain, from and after the closing, all non-IDO/TDO assets of Flexus including those related to Flexus’ Phase 1 FLT3 and CDK4/6 inhibitor, its earlier stage small-molecule Treg cancer immunotherapy programs, and its current personnel and facilities.
07:33 EDTMRKAdvaxis, Merck begin enrollment in Phase 1/2 of ADJX-PSA with Keytruda
Advaxis (ADXS) and Merck (MRK) announced that enrollment has initiated in the Phase 1/2 clinical trial evaluating the combination of ADXS-PSA, an investigational Lm-LLO immunotherapy, and Keytruda, the first anti-PD-1 therapy approved in the United States, in patients with previously treated, metastatic castration-resistant prostate cancer, or mCRPC. The clinical trial, KEYNOTE-046, is the first-in-human study of Advaxis's lead Lm-LLO immunotherapy candidate for prostate cancer. It is the second study initiated to evaluate the use of KEYTRUDA in the treatment of advanced prostate cancer. ADXS-PSA and KEYTRUDA are members of a class of cancer treatments known as immuno-oncology therapies. Data from preclinical studies suggest that Advaxis Lm-LLO immunotherapies in combination with a PD-1 antibody may lead to an enhanced anti-tumor immune response. The results from KEYNOTE-046 will determine the future clinical development program for the combination.
07:24 EDTJNJNeurotechnology Industry Organization to hold a conference
Subscribe for More Information
07:22 EDTMDVNMedivation price target raised to $180 from $132 at Canaccord
Subscribe for More Information
07:04 EDTMRKMerck's investigational Hep C therapy granted breakthrough therapy designations
Subscribe for More Information
April 7, 2015
07:14 EDTRHHBY, MRK, BMYEyeforpharma to hold a summit
Philadelphia 2015 Commercial Pharma Summit is being held in Philadelphia on April 7-8.
April 6, 2015
16:17 EDTBMYOn The Fly: Closing Wrap
Subscribe for More Information
14:34 EDTJNJDepomed price target raised to $30 from $27 at Roth Capital
Subscribe for More Information
12:44 EDTBMYOn The Fly: Midday Wrap
Subscribe for More Information
12:13 EDTBMYuniQure price target raised to $40 from $35 at Piper Jaffray
Subscribe for More Information
09:36 EDTJNJActive equity options trading on open
Subscribe for More Information
08:13 EDTBMYCelldex announces initiation of Phase 1/2 study of Varlilumab combination
Subscribe for More Information
07:33 EDTBMYBristol-Myers announces strategic collaboration with uniQure
Subscribe for More Information
06:21 EDTJNJJohnson & Johnson CEO comments on Asia expansion, WSJ reports
Subscribe for More Information
1 | 2 | 3 | 4 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use